Evidence map›Paper›PMID 34489909›Full record

ArticleFrontiers in microbiology2021

Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART.

Kelsie Brooks, F Harrison Omondi, Richard H Liang, Hanwei Sudderuddin, Bradley R Jones, Jeffrey B Joy, Chanson J Brumme, Eric Hunter, Zabrina L Brumme

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kelsie BrooksEmory Vaccine Center, Emory University, Atlanta, GA, United States.
F Harrison OmondiFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Richard H LiangBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Hanwei SudderuddinBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Bradley R JonesBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Jeffrey B JoyBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Eric HunterEmory Vaccine Center, Emory University, Atlanta, GA, United States.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
Deciphering the impact of sex in early subtype C HIV infection and during HARTR01AI172740 · NIAID · EMORY UNIVERSITY · PI Eric Hunter · 2022 to 2026
$4.3M
NIAID NIH HHS R01 AI051231NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI172740NIH HHS P51 OD011132Wellcome Trust
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) can persist as an integrated provirus, in a transcriptionally repressed state, within infected cells. This small yet enduring pool of cellular reservoirs that harbor replication-competent HIV is the main barrier to cure. Entry of viral sequences into cellular reservoirs begins shortly after infection, and cells containing integrated proviral DNA are extremely stable once suppressive antiretroviral therapy (ART) is initiated. During untreated HIV infection however, reservoir turnover is likely to be more dynamic. Understanding these dynamics is important because the longevity of the persisting proviral pool during untreated infection dictates reservoir composition at ART initiation. If the persisting proviral pool turns over slowly pre-ART, then HIV sequences seeded into it during early infection would have a high likelihood of persisting for long periods. However, if pre-ART turnover was rapid, the persisting proviral pool would rapidly shift toward recently circulating HIV sequences. One-way to estimate this turnover rate is from the age distributions of proviruses sampled shortly after therapy initiation: this is because, at the time of sampling, the majority of proviral turnover would have already occurred prior to ART. Recently, methods to estimate a provirus' age from its sequence have made this possible. Using data from 12 individuals with HIV subtype C for whom proviral ages had been determined phylogenetically, we estimated that the average proviral half-life during untreated infection was 0.78 (range 0.45-2.38) years, which is >15 times faster than that of proviral DNA during suppressive ART. We further show that proviral turnover during untreated infection correlates with both viral setpoint and rate of CD4+ T-cell decline during this period. Overall, our results support dynamic proviral turnover pre-ART in most individuals, which helps explain why many individuals' reservoirs are skewed toward younger HIV sequences. Broadly, our findings are consistent with the notion that active viral replication creates an environment less favorable to proviral persistence, while viral suppression creates conditions more favorable to persistence, where ART stabilizes the proviral pool by dramatically slowing its rate of decay. Strategies to inhibit this stabilizing effect and/or to enhance reservoir turnover during ART could represent additional strategies to reduce the HIV reservoir.

Indexed as

HIVpersistenceproviral half-lifereservoirwithin-host phylogenetic analysis

Identifiers

PMID34489909
PMCPMC8417368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.